CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 102 enrolled
Drug / intervention
Fluticasone Furoate Nasal Spray +1 moredrug
Likely dose
Fluticasone Furoate Nasal Spray 110mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00730756
NCT00730756Phase 2Completed

A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110 mcg for 4 Weeks in Adults and Adolescents With Irritant (Non-Allergic) Rhinitis

GlaxoSmithKline·interventional·Posted Aug 8, 2008·Updated Apr 6, 2017

In Brief

A Phase 2 clinical trial evaluating Fluticasone Furoate Nasal Spray and Placebo Nasal Spray for Rhinitis, Allergic, Perennial. Completed, enrolled 102 participants across 5 sites.

Detailed Summary

The purpose of this pilot study is to compare the effects (effectiveness and safety)of an intranasal corticosteroid (fluticasone furoate nasal spray \[FFNS\]) with a placebo nasal spray for the treatment of irritant (non-allergic) rhinitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesThailand
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 8, 2008
Enrollment StartMar 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.9 years ago

Interventions

Fluticasone Furoate Nasal Spraydrug

Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks

Placebo Nasal Sprayother

Matching placebo nasal spray intranasally once daily for 4 weeks